Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome - sprookjes - yvandenbroek - TriplyDB

Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome

Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome

http://www.wikidata.org/entity/Q24684801

about

Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen The CD44+/CD24- phenotype is enriched in basal-like breast tumors Gene expression patterns in ovarian carcinomas Proteotypic classification of spontaneous and transgenic mammary neoplasms Recent translational research: microarray expression profiling of breast cancer--beyond classification and prognostic markers?Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer HER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cells Biomarkers in triple negative breast cancer: A review Networking galore: intermediate filaments and cell migration Repeated observation of breast tumor subtypes in independent gene expression data sets The "portrait" of hereditary breast cancer ONCOMINE: a cancer microarray database and integrated data-mining platform DNA copy number alterations and expression of relevant genes in triple-negative breast cancer Proteome-wide profiling of the MCF10AT breast cancer progression model A phenotypic mouse model of basaloid breast tumors mRNA profiling reveals determinants of trastuzumab efficiency in HER2-positive breast cancer A time- and matrix-dependent TGFBR3-JUND-KRT5 regulatory circuit in single breast epithelial cells and basal-like premalignancies The Discovery of Novel Biomarkers Improves Breast Cancer Intrinsic Subtype Prediction and Reconciles the Labels in the METABRIC Data Set.Proteomics of breast cancer: principles and potential clinical applications.Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis.Use of immunohistochemical markers can refine prognosis in triple negative breast cancer.Contaminating cells alter gene signatures in whole organ versus laser capture microdissected tumors: a comparison of experimental breast cancers and their lymph node metastases.Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer.Identification of breast cancer patients with a high risk of developing brain metastases: a single-institutional retrospective analysis.Keratin 17 in premalignant and malignant squamous lesions of the cervix: proteomic discovery and immunohistochemical validation as a diagnostic and prognostic biomarker Progesterone receptor isoform functions in normal breast development and breast cancer Analysis of differentially expressed proteins in oral squamous cell carcinoma by MALDI-TOF MS.Blueberry phytochemicals inhibit growth and metastatic potential of MDA-MB-231 breast cancer cells through modulation of the phosphatidylinositol 3-kinase pathway.Clinical proteomics of breast cancer Correlations of ALDH1 expression with molecular subtypes and ABCG2 in breast cancer p16INK4a expression in basal-like breast carcinoma.Identification of prognostic genes for recurrent risk prediction in triple negative breast cancer patients in Taiwan.Characteristic genes in luminal subtype breast tumors with CD44+CD24-/low gene expression signature.Keratin 17 promotes epithelial proliferation and tumor growth by polarizing the immune response in skin.Is the small heat shock protein alphaB-crystallin an oncogene?Understanding tissue context influences on intratumour heterogeneity Modeling luminal breast cancer heterogeneity: combination therapy to suppress a hormone receptor-negative, cytokeratin 5-positive subpopulation in luminal disease.GeneFriends: an online co-expression analysis tool to identify novel gene targets for aging and complex diseases.Increased ID4 expression, accompanied by mutant p53 accumulation and loss of BRCA1/2 proteins in triple-negative breast cancer, adversely affects survival.Estrogen induced breast cancer is the result in the disruption of the asymmetric cell division of the stem cell.

P2860

Q21092375-E2A7D2E3-EC03-4445-8DEB-0D96A0180372 Q21092906-EBF07A77-A48A-433F-B359-EBF3DB3DB116 Q24644996-B44D14BC-0DA0-40A1-8E4F-DF392A79C38A Q24795869-D0EE4F97-B475-4FC2-9577-AB39CAF871AB Q24806447-7AAF0DE6-D060-4A76-A00F-6EC79227650B Q24810751-A8E68B5B-3E6F-49A9-8356-6BAA44732051 Q25257668-91658F2D-48E2-495A-986C-B47ACC1B71BB Q26775094-EB65E8FA-8D14-4BC3-A068-08D111F3FF9C Q27693294-E881E117-D169-4D96-9F06-A06778BC9509 Q28131820-D338FCEC-E283-4AB7-A104-0FDA6DA7B7A2 Q28238725-6769BB36-DF8C-43B4-9F40-5B45C8DD4F14 Q28255103-DB1C2010-D903-4C9F-800E-05F9F4F8B71A Q28271168-D3D5E7FC-5819-437C-839D-EB6DEAC4C0D0 Q28474333-1D9FD468-FDAA-4705-86E4-F895D574E312 Q28480588-4CBB3BC5-AA44-4ED6-AF5C-96D731862E79 Q28543647-357127A9-886A-4552-B468-08F48ADD6307 Q30410515-242C9DFA-A021-441D-A075-50E8B7237A34 Q30978083-F20F5069-2F13-41A9-99E1-612BC52F41F3 Q33245053-B638DEFC-0A21-4ECD-A5BB-E4AC4E72953C Q33280165-135649F6-023B-4C61-8B4B-6E4F580516AB Q33291587-C5D46814-5647-4A5C-B587-8F2B59049577 Q33302433-61AE0DD9-73C4-46C2-849C-10E7C1CCA395 Q33552870-1845FAA3-F488-4110-B469-CE51D7F5146F Q33553971-A714FB20-9B12-4C4D-88B5-6219EB43FF51 Q33634684-D3A7FBE2-DC8F-48BC-9EBA-7316FBC27149 Q33693898-D6DD83BD-D283-40CC-9222-686AF94BC4C7 Q33774554-682F2E01-4471-47FA-83CB-707AB221BD1B Q33820727-E674C1E6-EE7B-414E-8520-BC228714E64E Q33885885-3F8BD0BF-9410-4D09-8CB5-B2F18D4E9C37 Q33972932-BCA2FFC8-4CE9-467F-B99F-6D745B9F0409 Q34007463-26B3602B-C8EF-47D7-8859-3463C5762D23 Q34091380-94032B93-0879-4298-AB75-D1A29F6D82E3 Q34124530-BF9D13BB-59C8-4493-9491-21C442727C98 Q34164046-1E0782E5-7867-4DBA-AE69-D2BBB150B642 Q34245398-BFC58F06-84D7-445C-887A-C817B7C7F1C4 Q34267072-079701D9-524C-4D8E-858C-7BFE29E8E157 Q34296534-9A7B601F-0136-4736-8D0F-D41DFB4082C2 Q34435173-3276BEA1-A644-498E-BFB1-38564E43BC0C Q34489002-2F9BBC0E-5F22-4799-ACDE-B75531CA0C98 Q34508226-042D73F0-9A7D-48E3-9E45-AC64C88B3203

P2860

Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome

http://www.wikidata.org/entity/Q24684801

description

2002 nî lūn-bûn

@nan

2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Expression of cytokeratins 17 ...... mas with poor clinical outcome

@ast

Expression of cytokeratins 17 ...... mas with poor clinical outcome

@en

Expression of cytokeratins 17 ...... mas with poor clinical outcome

@nl

type

label

Expression of cytokeratins 17 ...... mas with poor clinical outcome

@ast

Expression of cytokeratins 17 ...... mas with poor clinical outcome

@en

Expression of cytokeratins 17 ...... mas with poor clinical outcome

@nl

prefLabel

Expression of cytokeratins 17 ...... mas with poor clinical outcome

@ast

Expression of cytokeratins 17 ...... mas with poor clinical outcome

@en

Expression of cytokeratins 17 ...... mas with poor clinical outcome

@nl

P1433

Q24684801-1675FF86-A603-4E96-A690-53CE0000018F

P1476

Q24684801-6149C753-2CEA-4604-9130-5DC3F7F2DD4C

P2093

Q24684801-084B8605-B6F7-4648-809E-4FBC830B1DC2

Q24684801-3D85F8AC-A45F-44CA-ADD8-B7BE5D7E8075

Q24684801-3F6BDA90-00EC-4621-A74C-884AC3A6B63D

Q24684801-572F2D83-8293-4C12-BA12-CC70AD0C47E2

Q24684801-75E1095D-0BEC-41CC-8563-9C22E7F65337

Q24684801-87A90DA1-7B26-474A-A53F-32E5842EDC2B

Q24684801-C6F48BDA-00FC-4F15-9FDA-6FA28A9A6AE0

Q24684801-CFCE0DD8-3ED0-4E89-B1A2-1A529220F80C

Q24684801-D18C0472-DE77-4312-BBF6-7384D5E93A6A

Q24684801-DF8DB6A6-8886-4B54-BFAC-D52EF97F026A

P2860

Q24684801-0F90259D-1A9C-41D8-9C54-23E7BD3E43BF

Q24684801-2B8D66BF-D227-4C08-92A9-4A0F22C376FC

Q24684801-2EB72DED-74F5-4898-8C9B-7FDA1680C1FC

Q24684801-30190FE7-783A-48A6-91D8-44A9D101D67C

Q24684801-3CCBE98E-68B7-4C94-BBFD-35FBBA4864F2

Q24684801-680B3FB5-8951-459C-BEFE-4221230AD014

Q24684801-8C1B9719-D2CD-4B41-8E65-11ADA2B9CF09

Q24684801-96200986-79FF-4DCE-90AD-4BC500831138

Q24684801-9A4E5990-408E-4208-AC3A-42BCE7B62922

Q24684801-C8E89286-3499-427B-BF87-03BF62F8E055

P304

Q24684801-737613E8-0190-4C33-A88F-06994B80966C

P31

Q24684801-6E6DDCAE-40F8-49D1-92DB-B7718C393D29

P3181

Q24684801-A355B01E-864F-4042-AB19-23FD7CF7CCB7

P356

Q24684801-9B997A7C-DA43-4941-8010-4C4253F731C2

P407

Q24684801-823AD016-DC8A-4CF9-891F-C738CBE903B1

P433

Q24684801-CAB2B9A9-0CB9-4056-A9CB-65A4FA37F7FA

P478

Q24684801-EBD0BA36-1698-4825-807E-280DF42937FB

P50

Q24684801-577F8CE9-76AE-4F19-96F0-1B903C64D4B3

Q24684801-8C6E52E6-6094-45C1-BF21-E4C28AACC254

Q24684801-C3B1E127-2E44-46AA-A696-6354FAB190F0

Q24684801-CB6023FB-F0A4-4DDA-8CF0-D807D6A202E9

P577

Q24684801-6992A7D7-BE23-42BA-BFE0-42EBAB6AD2A2

P5875

Q24684801-0A04FD8F-7011-4DB4-B828-FA702FDADAFD

P698

Q24684801-953262A0-C03D-47EE-BA34-50B6679F64AF

P932

Q24684801-0718463A-9FE8-4232-A869-AC22D43B3A3D

P3181

P356

S0002-9440(10)64476-8

P1433

The American Journal of Pathology

P1476

Expression of cytokeratins 17 ...... mas with poor clinical outcome

@en

P2093

Doug Ross

http://www.w3.org/2001/XMLSchema#string

Frank Mross

http://www.w3.org/2001/XMLSchema#string

Guido Sauter

http://www.w3.org/2001/XMLSchema#string

Holger Dieterich

http://www.w3.org/2001/XMLSchema#string

Joachim Torhorst

http://www.w3.org/2001/XMLSchema#string

Juha Kononen

http://www.w3.org/2001/XMLSchema#string

Markus Zuber

http://www.w3.org/2001/XMLSchema#string

Ossi R Köchli

http://www.w3.org/2001/XMLSchema#string

Pat Brown

http://www.w3.org/2001/XMLSchema#string

Phillippe Haas

http://www.w3.org/2001/XMLSchema#string

P2860

Expression monitoring by hybridization to high-density oligonucleotide arrays

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Molecular portraits of human breast tumours

Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up

Tissue microarrays for rapid linking of molecular changes to clinical endpoints

Tissue microarrays for high-throughput molecular profiling of tumor specimens

Making and reading microarrays.

College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Summary. Members of the Cancer Committee.

Prognostic and predictive factors in breast cancer by immunohistochemical analysis.

Analysis of MUM1/IRF4 protein expression using tissue microarrays and immunohistochemistry.

P304

1991-6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

5059046

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/S0002-9440(10)64476-8

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

161

http://www.w3.org/2001/XMLSchema#string

P50

Olli-Pekka Kallioniemi

Charles M. Perou

Matt van de Rijn

P577

2002-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11005495

http://www.w3.org/2001/XMLSchema#string

P698

12466114

http://www.w3.org/2001/XMLSchema#string

P932

1850928

http://www.w3.org/2001/XMLSchema#string